^(131)I联合^(99)Tc-MD治疗Graves眼病疗效观察  

Clinical effect of ^(99)Tc-MD combined with ^(131)I in the treatment of Graves ophthalmopathy

作　　者：梁坤[1] 李诗运[1] 戴儒奇[1] 

机构地区：[1]海南省人民医院核医学科,海南海口570311

出　　处：《海南医学》2017年第17期2811-2813,共3页Hainan Medical Journal

基　　金：海南省自然科学基金(编号:806117)

摘　　要：目的探讨碘131(^(131)I)联合锝亚甲基二膦酸盐注射液(^(99)Tc-MD)治疗Graves眼病(GO)的临床效果。方法回顾性分析2011年1月至2016年2月在海南省人民医院治疗的270例Graves眼病患者的临床资料,根据治疗方式将患者分为观察组(143例)和对照组(127例)。观察组采用^(131)I联合^(99)Tc-MD治疗,对照组仅使用^(131)I治疗,两组患者均规范治疗12个月,比较两组患者的甲亢及突眼的临床疗效。结果观察组和对照组患者治疗甲亢总有效率分别为95.10%和86.62%,差异无统计学意义(P>0.05);观察组和对照组患者治疗突眼总有效率分别为70.63%和41.73%,差异有统计学意义(P<0.05),其中Ⅰ度有效率分别为92.86%和65.79%,Ⅱ度有效率分别为71.83%和34.92%,差异均有统计学意义(P<0.05),Ⅲ度有效率分别为36.67%和23.08%,差异无统计学意义(P>0.05);治疗后,观察组患者的突眼度、甲状腺容积分别为(17.78±2.42)mm、(25.79±3.23)g,明显小于对照组患者的(18.85±2.73)mm、(27.56±3.51)g,差异均有统计学意义(P<0.01)。两组患者均未现严重不良反应。结论^(131)I联合^(99)Tc-MD治疗Graves眼病,能提高患者的突眼治疗效果,改善患者的临床症状,值得临床参考。Objective To explore the clinical effects of the Technetium Methylenediphosphonate Injection （99Tc-MD） combined with 131I in treatment of Graves ophthalmopathy （GO）. Methods A total of 270 patients with GO in Hainan Central Hospital from Jan. 2011 to Feb. 2016 were randomly divided into the observation group （n=143） and the control group （n=127）, using random number table method. The observation group was treated with 131I combined with 99Tc-MD, while the control group was only treated with 131I. The clinical efficacy and treatment outcome of hyper-thyroidism and exophthalmos after standard treatment for 12 months were compared. Results There was no signifi-cant difference in the total efficiency between the observation group （95.10%） and the control group （86.62%）, P〉0.05. For exophthalmos, the total effective rate in the observation group （70.63%） was significantly higher than that in the control group （41.73%）, P〈0.05. TheⅠgrade effective rate was 92.86%in the observation group and 65.79%in the control group （P〈0.05）, and theⅡgrade effective rate was 71.83%and 34.92%, respectively （P〈0.05）. There was no significant differences in theⅢgrade effective rate between the two groups （36.67%vs 23.08%, P〉0.05）. The exoph-thalmos degree and thyroid volume were （17.78 ± 2.42） mm and （25.79 ± 3.23） g in the observation group, which were significantly lower than （18.85±2.73） mm and （27.56±3.51） g in the control group （P〈0.01）. No adverse reactions were observed. Conclusion 131I combined with 99Tc-MD therapy in the treatment of Graves ophthalmopathy can increase the clinical efficacy, improve the clinical symptoms of the patients, which is recommended in clinical practice.

关 键 词：锝亚甲基二膦酸盐注射液 碘131 甲状腺亢进 突眼 治疗效果 

分 类 号：R771.3[医药卫生—眼科]